English  |  正體中文  |  简体中文  |  Total items :0  
Visitors :  50694013    Online Users :  245
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 		 
Scope Adv. Search
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR
About TAIR

Browse By
Institution
Author
Title
Date
Statistics Chart
Institution Facts
Trend

News
2019臺灣學術機構典藏
研討會
機構典藏系統RC7版本已
發佈

Copyright
Publisher & Journal Policy
TAIR Copyright Conference Minutes

Related Links
機構典藏計畫網站
ROAR
OpenDOAR
SHERPA
OAIster
JAIRO
Ira
DSPACE
RWWR
臺大學術典藏NTU Scholars
Taiwan Academic Institutional Repository >  Browse by Author

"| su t h"

Return to Browse by Author
Sorting by Title Sort by Date

Showing items 1-41 of 41  (1 Page(s) Totally)
1 
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2021-07-12T02:44:50Z Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load Tseng T.-C; | Liu C.-J; | HUNG-CHIH YANG; | Su T.-H; | Wang C.-C; | Chen C.-L; | Fang-Tzu Kuo S; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:50Z High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load Tseng T.-C; | Liu C.-J; | HUNG-CHIH YANG; | Su T.-H; | Wang C.-C; | Chen C.-L; | Kuo S.F.-T; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:49Z Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion HUNG-CHIH YANG; | Chen C.-L; | Shen Y.-C; | Peng C.-Y; | Liu C.-J; | Tseng T.-C; | Su T.-H; | Chuang W.-L; | Yu M.-L; | Dai C.-Y; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:49Z Young chronic hepatitis b patients with nucleos(t)ide analogue-induced hepatitis b e antigen seroconversion have a higher risk of HBV reactivation Tseng T.-C; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Wang C.-C; | Chen C.-L; | Kuo S.F.-T; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:48Z Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads Tseng T.-C; | Liu C.-J; | HUNG-CHIH YANG; | Su T.-H; | Wang C.-C; | Chen C.-L; | Hsu C.-A; | Fang-Tzu Kuo S; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:47Z Pegylated interferon-�\2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial Liu C.-H; | Huang C.-F; | Liu C.-J; | Dai C.-Y; | Liang C.-C; | Huang J.-F; | Hung P.-H; | Tsai H.-B; | Tsai M.-K; | Chen S.-I; | Lin J.-W; | Yang S.-S; | Su T.-H; | HUNG-CHIH YANG; | Chen P.-J; | Chen D.-S; | Chuang W.-L; | Yu M.-L; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:47Z Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers Tseng T.-C; | Liu C.-J; | Chen C.-L; | HUNG-CHIH YANG; | Su T.-H; | Wang C.-C; | Yang W.-T; | Kuo S.F.-T; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:46Z Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters Tseng T.-C; | Liu C.-J; | Yang W.-T; | Chen C.-L; | HUNG-CHIH YANG; | Su T.-H; | Wang C.-C; | Kuo S.F.-T; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:45Z Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: Clinical and mechanistic implications Wu H.-L; | Kao J.-H; | Chen T.-C; | Wu W.-H; | Liu C.-H; | Su T.-H; | HUNG-CHIH YANG; | Chen D.-S; | Chen P.-J; | Liu C.-J.
臺大學術典藏 2021-07-12T02:44:43Z Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection Tseng T.-C; | Liu C.-J; | Chen C.-L; | Yang W.-T; | HUNG-CHIH YANG; | Su T.-H; | Wang C.-C; | Kuo S.F.-T; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:43Z Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection Cheng H.-R; | Kao J.-H; | Wu H.-L; | Tseng T.-C; | Liu C.-H; | HUNG-CHIH YANG; | Su T.-H; | Chen P.-J; | Chen D.-S; | Liu C.-J.
臺大學術典藏 2021-07-12T02:44:42Z Comparison of abbott realtime HCV genotype II with versant line probe assay 2.0 for hepatitis C virus genotyping Liu C.-H; | Liang C.-C; | Liu C.-J; | Lin C.-L; | Su T.-H; | HUNG-CHIH YANG; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:42Z Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy Liang C.-C; | Liu C.-H; | Chung C.-S; | Lin C.-K; | Su T.-H; | HUNG-CHIH YANG; | Liu C.-J; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:41Z Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers Tseng T.-C; | Liu C.-J; | HUNG-CHIH YANG; | Chen C.-L; | Yang W.-T; | Tsai C.-S; | Kuo S.F.-T; | Verbree F.C; | Su T.-H; | Wang C.-C; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:41Z Peginterferon plus weight-based ribavirin for treatment-na?ve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial Liu C.-H; | Huang C.-F; | Liu C.-J; | Dai C.-Y; | Huang J.-F; | Lin J.-W; | Liang C.-C; | Yang S.-S; | Lin C.-L; | Su T.-H; | HUNG-CHIH YANG; | Chen P.-J; | Chen D.-S; | Chuang W.-L; | Kao J.-H; | Yu M.-L.
臺大學術典藏 2021-07-12T02:44:40Z Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na?ve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial Liu C.-H; | Huang C.-F; | Liu C.-J; | Dai C.-Y; | Huang J.-F; | Lin J.-W; | Liang C.-C; | Yang S.-S; | Lin C.-L; | Su T.-H; | HUNG-CHIH YANG; | Chen P.-J; | Chen D.-S; | Chuang W.-L; | Kao J.-H; | Yu M.-L.
臺大學術典藏 2021-07-12T02:44:40Z Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial Liu C.-H; | Liu C.-J; | Huang C.-F; | Lin J.-W; | Dai C.-Y; | Liang C.-C; | Huang J.-F; | Hung P.-H; | Tsai H.-B; | Tsai M.-K; | Lee C.-Y; | Chen S.-I; | Yang S.-S; | Su T.-H; | HUNG-CHIH YANG; | Chen P.-J; | Chen D.-S; | Chuang W.-L; | Yu M.-L; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:39Z Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naive Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study Liu C.-H; | Sheng W.-H; | Sun H.-Y; | Hsieh S.-M; | Lo Y.-C; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Liu W.-C; | Chen P.-J; | Chen D.-S; | Hung C.-C; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:38Z Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection Yang W.-T; | Wu L.-W; | Tseng T.-C; | Chen C.-L; | HUNG-CHIH YANG; | Su T.-H; | Wang C.-C; | Kuo S.F.-T; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Liu C.-J; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:36Z Fibrosis-4 Index Helps Identify HBV Carriers with the Lowest Risk of Hepatocellular Carcinoma Tseng T.-C; | Liu C.-J; | Su T.-H; | Yang W.-T; | Chen C.-L; | HUNG-CHIH YANG; | Wang C.-C; | Kuo S.F.-T; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:36Z Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection Liu C.-H; | Liu C.-J; | Su T.-H; | Fang Y.-J; | HUNG-CHIH YANG; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:34Z A noninvasive diagnosis of hepatic fibrosis by BioFibroScore? in chronic hepatitis C patients Liu C.-H; | Liu C.-J; | Hong C.-M; | Su T.-H; | HUNG-CHIH YANG; | Chen K.-M; | Huang Y.-P; | Yeh Y.-M; | Tien H.-L; | Liu Y.-C; | Kao J.-H; | Chen D.-S; | Chen P.-J.
臺大學術典藏 2021-07-12T02:44:33Z Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan Liu C.-H; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Hong C.-M; | Tseng T.-C; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:33Z Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients with Chronic Hepatitis C Virus Infection Liu C.-H; | Chen Y.-S; | Wang S.-S; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Hong C.-M; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:32Z Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection Liu C.-H; | Sun H.-Y; | Liu C.-J; | Sheng W.-H; | Hsieh S.-M; | Lo Y.-C; | Liu W.-C; | Su T.-H; | HUNG-CHIH YANG; | Hong C.-M; | Tseng T.-C; | Chen P.-J; | Chen D.-S; | Hung C.-C; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:32Z Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection Tseng T.-C; | Liu C.-J; | Su T.-H; | Yang W.-T; | Chen C.-L; | HUNG-CHIH YANG; | Kuo S.F.-T; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:30Z Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B Papatheodoridis G.V; | Manolakopoulos S; | Su T.-H; | Siakavellas S; | Liu C.-J; | Kourikou A; | HUNG-CHIH YANG; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:30Z Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study Liu C.-H; | Huang Y.-J; | Yang S.-S; | Chang C.-H; | Yang S.-S; | Sun H.-Y; | Liu C.-J; | Liu W.-C; | Su T.-H; | HUNG-CHIH YANG; | Hong C.-M; | Tseng T.-C; | Chen P.-J; | Chen D.-S; | Hung C.-C; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:29Z Profile and value of FIB-4 in patients with dual chronic hepatitis C and B Liu C.-J; | Tseng T.-C; | Yang W.-T; | Su T.-H; | HUNG-CHIH YANG; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:29Z Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan Liu C.-H; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Hong C.-M; | Tseng T.-C; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:27Z Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis Liu C.-H; | Shih Y.-L; | Yang S.-S; | Lin C.-L; | Fang Y.-J; | Cheng P.-N; | Chen C.-Y; | Peng C.-Y; | Hsieh T.-Y; | Chiu Y.-C; | Su T.-H; | Liu C.-J; | HUNG-CHIH YANG; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:27Z Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection Liu C.-H; | Su T.-H; | Liu C.-J; | Hong C.-M; | HUNG-CHIH YANG; | Tseng T.-C; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:25Z High Level of Hepatitis B Core�VRelated Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load Tseng T.-C; | Liu C.-J; | Hsu C.-Y; | Hong C.-M; | Su T.-H; | Yang W.-T; | Chen C.-L; | HUNG-CHIH YANG; | Huang Y.-T; | Fang-Tzu Kuo S; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:24Z HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis Tseng T.-C; | Liu C.-J; | Chang C.T; | Su T.-H; | Yang W.-T; | Tsai C.-H; | Chen C.-L; | HUNG-CHIH YANG; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:24Z Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy Tseng T.-C; | Peng C.-Y; | Hsu Y.-C; | Su T.-H; | Wang C.-C; | Liu C.-J; | HUNG-CHIH YANG; | Yang W.-T; | Lin C.-H; | Yu M.-L; | Lai H.-C; | Tanaka Y; | Nguyen M.H; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:23Z Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data Hong C.-M; | Liu C.-H; | Su T.-H; | HUNG-CHIH YANG; | Chen P.-J; | Chen Y.-W; | Kao J.-H; | Liu C.-J.
臺大學術典藏 2021-07-12T02:44:21Z Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan Su H.-J; | Kao J.-H; | Tseng T.-C; | HUNG-CHIH YANG; | Su T.-H; | Chen P.-J; | Liu C.-J.
臺大學術典藏 2021-07-12T02:44:21Z High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy Chang W.-Y; | Chiu Y.-C; | Chiu F.-W; | Hsu Y.-C; | Tseng T.-C; | Cheng P.-N; | Yang S.-S; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Liu C.-H; | Chen P.-J; | Chen D.-S; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:20Z Clinical and histologic features of patients with biopsy-proven metabolic dysfunction-associated fatty liver disease Huang S.-C; | Su H.-J; | Kao J.-H; | Tseng T.-C; | HUNG-CHIH YANG; | Su T.-H; | Chen P.-J; | Liu C.-J.
臺大學術典藏 2021-07-12T02:44:19Z Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load Tseng T.-C; | Liu C.-J; | Yang W.-T; | Hsu C.-Y; | Hong C.-M; | Su T.-H; | Tsai C.-H; | Chen C.-L; | HUNG-CHIH YANG; | Liu C.-H; | Chen H.-H; | Chen P.-J; | Kao J.-H.
臺大學術典藏 2021-07-12T02:44:18Z Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters Lin S.-R; | Yang T.-Y; | Peng C.-Y; | Lin Y.-Y; | Dai C.-Y; | Wang H.-Y; | Su T.-H; | Tseng T.-C; | Liu I.-J; | Cheng H.-R; | Shen Y.-C; | Wu F.-Y; | Liu C.-J; | Chen D.-S; | Chen P.-J; | HUNG-CHIH YANG; | Kao J.-H.

Showing items 1-41 of 41  (1 Page(s) Totally)
1 
View [10|25|50] records per page

DSpace Software Copyright © 2002-2004  MIT   &  Hewlett-Packard   /   Enhanced by   NTU Library IR team